TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Moleculin Biotech ( (MBRX) ) has provided an update.
On September 9, 2025, Moleculin Biotech announced updates on its pivotal Phase 2B/3 MIRACLE trial for Annamycin in combination with cytarabine for treating relapsed or refractory acute myeloid leukemia. The trial is expanding globally, with recruitment efforts accelerating across Europe and the US, aiming to recruit 45 subjects by Q4 2025 for initial data unblinding. This expansion is expected to enhance the company’s operational efficiency and provide early visibility into trial outcomes, which is advantageous for investors.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Their lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases, avoiding common drug resistance and cardiotoxicity issues.
Average Trading Volume: 6,426,021
Technical Sentiment Signal: Sell
Current Market Cap: $11.36M
Find detailed analytics on MBRX stock on TipRanks’ Stock Analysis page.